Berkeley, United States
Actym Therapeutics, Inc. is pioneering advancements in immuno-oncology by focusing on the challenging task of converting “cold” tumors to “hot” to effectively trigger anti-tumor immune responses without widespread systemic cytokine exposure. Their flagship product, ACTM-838, utilizes the innovative STACT™ platform (S. Typhimurium-Attenuated Cancer Therapy), incorporating genetically modified bacterial vectors to locally deliver and amplify therapeutic payloads in tumor sites.
The company's approach, founded in 2017 in the United States, is backed by recent $25.50M Series A investment from prominent investors like Illumina Ventures, Boehringer Ingelheim, Panacea Venture, JLo Ventures, and GKCC. Key attention is directed towards upcoming clinical updates from their Phase 1a/b trial, anticipated in 3Q 2025. The STACT™ platform's modularity hints at potential applications beyond oncology, positioning Actym as a transformative player reshaping medicine through delivery breakthroughs.
